Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies

I-MOVE/I-MOVE+ group

Research output: Contribution to journalArticlepeer-review

Abstract

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.

Original languageEnglish
Article number18-00086
JournalEurosurveillance
Volume23
Issue number9
DOIs
Publication statusPublished - Mar 1 2018

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health
  • Virology

Fingerprint Dive into the research topics of 'Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies'. Together they form a unique fingerprint.

Cite this